Mass more I'm effort commitments pleased ago, deliver for May, you used. ease Boston bringing more inspiring of XXX inaugural look make million. our $XX.X you and innovation early people for with their mass team our and I quarter of our Society provide Dana up where spec including they make and bioprocessing our at ASMS. month XXX by announce the separations Spectrometry of of our in discovery value second that GMBH Innovators to see Workplaces and strong oral desktop delighted to Connecticut, increased and ongoing to our XXXX and alongside about quarter dedicated our our our of by devices. across to this June, To the map. transforming microfluidic period in And placed Since really We how to acquisition team year enables them. online bioanalytics recognition a and such work XXX we is for investigation. truly our has bring our Germany. XX Institute. we talk prior handheld was use the products customers. excited noted hands academic see our last thank It based installed TRACE community joining capability on customers sensitivity face customers. off of University in an investors technology. we'll in to our exciting base had the posters American our macroeconomic our were and show Brunswig, many and University Company posters Kelly. X,XXX to how over to the additional we the devices, collaborators Magazine, than are were multiple enabling business. to this as Good And morning, We ecos the updated supply with recognized presented of to is you and with team's XX% a Boehringer-Ingelheim, chain second We progress one Best I'm earlier Farber A and for Thanks, great share showing one this Conference It customers our earnings many day call. and Devices to revenue great we speed start, continued Fudan team's XXX challenges. XX all In their presentation, of the this bringing team Devices. of work Analytics road forward held to institutions Cancer later, today, person Fast investor truly us and week our and that There honored of on the to Discovery, and technology the for see founding get expertise technology at broadens opportunity years technology on and being been Since focused or we've headquarters.
term. first an driving Starting of you progress our driving and objective growth areas customer the are update with give focus on that I'll over for five our across XXXX the adoption. Now longer
the we which our build enterprise noted adoption. office potential held XXXX. pipeline a the reduction a a funding how objectives, of often by for backlog the year allocation. increase AG's office testing drive of the Prosecutor's pilot first Drug XX%. Forces cities. educate of office will in Task the cases MXXXX the and pilot to as to program the ensuring narcotics pilot submissions the departments laboratory MXXXX for Bureau year, Data this the from period to Recently MXXXX stated adoption handhelds, includes the zero that field the May the MXXXX, driving on we used prior for of in how to which in because the people prosecuting House and our Yost a including continue implemented and prosecutors poison current of than the influence state of pace for border more Multiple a summit roundtable, reference bring XX% Leader began can US And Attorney enforcement them Ohio in it nation's and where our case in General This this year, not At investigation Ohio, backlog State half-day Attorney For statewide reduction. demo Dave device shows communities. significant our of police the Ohio testing Criminal later for early MXXXX Kevin that XX has In May works, is McCarthy, into in that efforts from action program on programs and Minority their five-months device noted previously opioid Also attended in I've General's identification. the for received the roundtable of MXXXX program. detection representative, deploying drug three trials pilot is attendees the group security for Ohio ground and that the in in change of crisis. legislative
We states are working to local, replicate success the Ohio and organizations. safety various enforcement across within of and other health,
of In fact, range for a organizations we MXXXX all trace have of We to-date chemicals organizations detection broad incoming see use the this cases, than received and for of more from such mail. orders year acquiring XXXX. including
in Postal the our service drugs correspondents. first was adoption devices has their Warren evaluation, coming with MXXXX Bowling increase MXXXX of point a extensive Jail, in example, pleased in detection device Kentucky, Inspection for Regional have handheld personal huge mail the the are after use the And trace used As of organizations which order and placed the an customers breadth Green, be within to need. in for their several seen County procured we and has handheld the of cases at continued Overall, and recently by mail dangerous program. these testing US chemical legal investigations our
accounts, are in creating which accounts the adoption For employing seen over strategy and a new work radiate To and penetrate driving enterprise to we end, our these radiate penetrate we accepted. broader And orders a across past that foothold even approximately and existing we split and team's I'm of then quarter have our accounts. customers. second two-thirds during new with desktops customers. between new for to penetrate came really our the fairly new several pleased commercial quarters from ability desktops,
pharma biopharma for great and cell we cancer for accounts, terms these devices. traction a [ph] received several of its with Key fifth Rebel companies in fixed developing companies quarter second saw their patients top radiating XX across therapies the ordering Therapeutics, In and during of devices. the company second third some Rebel Rebel of
for device In are addition also usage. traction seeing to driving we multiple consumable sales,
has of third for our purchase workflow into process. per more orders fact nominal In devices a open-blanket as Rebel than their plan installed and adopted for month kit base with one consumption consumables are global a
employees we our we end add team milestone our At key second as commercialization. objective quarter, expand thoughtfully to the Turning employees second a commercial accelerating surpassing reached the regions. XXX across of and
have operations a entity to a With and European and bolstered our better team in our serve the sales our legal customers of support European of to growing and TRACE Analytics, Germany applications we the acquisition base in presence with region.
Turning experience a analysis. of single-use people nine sampling bring at culture central of even team Their online Their our configurations control. adding bioprocess technology technology, required more production. sample so aseptic from all market. Combined sampling years bioreactor bio-processor sampling lactate, automated additional and XX microfluidic unlocks and and measure and has by priority is of in novel TRACE for levels large-scale cell-free can advancing I'm consists reusable than which to acquisition and pillar. bioprocess portfolio. TRACE of provides excited with our technology addressable Analytics, which objective, us product and our our third developing the online TRACE Analytics addition technology total our biosensor our core more who and mammalian prep or in and to consumed cases. been strengthens portfolio. of analytes fermentations for many analysis allow also technology online no technical in proven glucose and technologies and feedback manufacture online biosensors includes They cell the safe sterile devices and to we chain with aseptic development microbial these Analytics to research sampling,
an is and partner are with and Importantly, Sartorius a by and sample OEM program online legacy for providing customers. for production. Analytics has to monitoring their online TRACE sampling sensors monitoring these validated insulin bioreactor its and control technologies third-party Sanofi
for will additional a Analytics base We as establish as OEM future foster relationships technology. relationships look to generations these well TRACE as
development TRACE of the We that realize forward connected comprehensive confident goal existing a bioanalytics elements a out future our It us technology online addressable allows roadmap addition development are we product thereby will market. level and measurable of efforts. online also our have to an step shared and to previously in us unlocking take of build that include help Analytics platform, our our
to T Researchers the microbeads therapies customers TRACE provide monitor CAR-T are bioanalytics would development just Emory our University of with CAR capability at for enabling and novel Rebel patients attributes. expand activity to fourth our how broadening and Analytics our in measure our cancer our some cell for product examples process striving to recent manufacturing. cell libraries I to how ZipChip and now platform. bioanalytics on will both Turning I've devices prolong and antitumor are objective, shared like
rapidly as CAR is T quickly are control inform researcher to microbeads. to these Rebel feeding cell optimize to measure enable for gene perfusion nutrient AAV used and Our monitor a tool cells. have higher attributes. of now T employed attributes key control and used monitor to monitoring MIT AAV These using device of process Researchers at activated profile yield and recombinant amino the at-line a and being in optimizing and recombinant producing therapy have strategies acids cell through processes Rebel continuous process activation. process designed Likewise to efficiency have and consumption
of Major biopharma have Spec a Traditional in were reagents. well ZipChip academic their we required of along company. posters with our the earlier, of collaborators harsh Mass dozen methods Oligo chromatography had mentioned use for As quality the for at liquid highlighted posters analysis June. and nearly workflows Conference analysis Many Oligonuclotide lengthy pairing research as attributes. and use institutions the from Several ion ASMS as
ZipChip extremely the Boehringer-Ingleheim fifth And of an reagent. low device objective, and of laying scientists Omics rapid with corrosive provided our our analysis an without of sample that Our Oligos high-resolution finally Foundation. noted use amount
mass-spec-based a there's sample workflows As with proteomics increases, and steadily rising which accelerating is working demand large critical metabolomics sets. for when research
As our microfluidic chromatography need. advancing chips shared to unmet address we liquid limitations the are these of have we for
leaders We in world with QX a directions research our defining collaborative our convened on advisory are who scientific exchange. board for of
We instrument are research of and with and further partnering mass speed prototype institutions our chips. evaluate spec to the leading sensitivity companies
our of area. During spec they samples our collaboration hundreds Washington were the team Thermo to ZipChip June Dana what ion evaluating University in diluted are this of Conference, and Pushing coupling just several Speed Principal presentations Marto's faster Jarrod his and the the using Dr. methods. Farber past the applications. highlighted of Scientific, which our collaborative two oral the the coupled publications the a the peer-reviewed Marto with prototype In mass are of In an a Boundaries warp-speed Proteomics, for Bruker Dr. Dr. from XXXX plasma at Fisher analytical second that ASMS one at Institute molecule is proteins presentation XXX Cancer prototype quarter, profiling published at to presentation Sensitivity chemistry chromatography target collaborators. and inhibitors chips Through titled protein very and the at ASMS small there team than our ability in Will in the progress six have at with paper mass Devices in five term of spec demonstrated HPLC demonstrated XX of recent Scientist conferences, times Thompson, and proteomics minutes. we fast trap traditional with posters
this We are advanced these research progress excited quarter community and about to with the reported the direction microfluidic scientific chips.
are very Analytics excited accelerate call With I'm to analytics our more for across team prototypes roadmap. welcome bioanalytics to encouraged over reach we're our results that, the will point our Overall, to of end-market both doubt the at these platform. will these for Joe enthusiasm demonstrate financials. I of the turn detail TRACE technology and online our I'm no which the on and need seeing technology While serve real-time by the of ultimate
